Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it has completed enrollment of the Contrast PMR study, a prospective, multi-ce…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.